Gene transfer to hemophilia A mice via oral delivery of FVIII-chitosan nanoparticles

Journal of Controlled Release

Volumn 132, Issue 3, 2008, Pages 252-259

  Bowman, Katherine ^a   Sarkar, Rita ^b   Raut, Sanj ^c   Leong, Kam W ^d,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^d Duke University   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chitosan; Gene medicine; Hemophilia therapy; Non viral gene delivery; Oral delivery

Indexed keywords

ATTRACTIVE STRATEGIES; CHITOSAN NANO PARTICLES; DELIVERY SYSTEMS; GENE DELIVERIES; GENE THERAPIES; HEMOPHILIA THERAPY; MEDICINE APPLICATIONS; NON-VIRAL GENE DELIVERY; ORAL ADMINISTRATIONS; ORAL DELIVERIES; ORAL DELIVERY; POLYPLEXES; THROMBIN GENERATIONS; TRANSGENE; VIRAL GENES;

CHITIN; CHITOSAN; CHROMOGENICS; DNA; GENE TRANSFER; GENES; GENETIC ENGINEERING; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOSTRUCTURES; NUCLEIC ACIDS; ORGANIC ACIDS;

AMINES;

BLOOD CLOTTING FACTOR 8; CHITOSAN; CHITOSAN BLOOD CLOTTING FACTOR 8 DNA COMPLEX; NAKED DNA; NANOPARTICLE; PLASMID DNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA VECTOR; DRUG EFFICACY; DRUG MEGADOSE; GENE TRANSFER; GENETIC TRANSFECTION; HEMOPHILIA A; KNOCKOUT MOUSE; LOW DRUG DOSE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; TRANSGENE;

ADMINISTRATION, ORAL; ANIMALS; CHITOSAN; DISEASE MODELS, ANIMAL; DNA; DOGS; FACTOR VIII; FEASIBILITY STUDIES; GENE THERAPY; HEMOPHILIA A; HEMOSTASIS; HUMANS; MICE; MICE, KNOCKOUT; NANOPARTICLES; THROMBIN; TIME FACTORS; TISSUE DISTRIBUTION; TRANSFECTION;

EID: 56949084718     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2008.06.019     Document Type: Article

References (46)

1. VandenDriessche T., Collen D., and Chuah M.K. Gene therapy for the hemophilias. J. Thromb. Haemost. 1 7 (2003) 1550-1558
2. Balague C., Zhou J., Dai Y., Alemany R., Josephs S.F., Andreason G., Hariharan M., Sethi E., Prokopenko E., Jan H.Y., Lou Y.C., Hubert-Leslie D., Ruiz L., and Zhang W.W. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 95 3 (2000) 820-828
3. Sarkar R., Tetreault R., Gao G., Wang L., Bell P., Chandler R., Wilson J.M., and Kazazian Jr. H.H. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103 4 (2004) 1253-1260
4. Scallan C.D., Liu T., Parker A.E., Patarroyo-White S.L., Chen H., Jiang H., Vargas J., Nagy D., Powell S.K., Wright J.F., Sarkar R., Kazazian H.H., McClelland A., and Couto L.B. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood 102 12 (2003) 3919-3926
5. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., McCormack M.P., Wulffraat N., Leboulch P., Lim A., Osborne C.S., Pawliuk R., Morillon E., Sorensen R., Forster A., Fraser P., Cohen J.I., de Saint Basile G., Alexander I., Wintergerst U., Frebourg T., Aurias A., Stoppa-Lyonnet D., Romana S., Radford-Weiss I., Gross F., Valensi F., Delabesse E., Macintyre E., Sigaux F., Soulier J., Leiva L.E., Wissler M., Prinz C., Rabbitts T.H., Le Deist F., Fischer A., and Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 5644 (2003) 415-419
6. Chuah M.K., Schiedner G., Thorrez L., Brown B., Johnston M., Gillijns V., Hertel S., Van Rooijen N., Lillicrap D., Collen D., VandenDriessche T., and Kochanek S. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 101 5 (2003) 1734-1743
7. Sarkar R., Xiao W., and Kazazian Jr. H.H. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J. Thromb. Haemost. 1 2 (2003) 220-226
8. Blouin V., Brument N., Toublanc E., Raimbaud I., Moullier P., and Salvetti A. Improving rAAV production and purification: towards the definition of a scaleable process. J. Gene Med. 6 Suppl 1 (2004) S223-S228
9. Ferber D. Gene therapy. Safer and virus-free?. Science 294 5547 (2001) 1638-1642
10. Pouton C.W., and Seymour L.W. Key issues in non-viral gene delivery. Adv. Drug Deliv. Rev. 46 1-3 (2001) 187-203
11. Ye P., Thompson A.R., Sarkar R., Shen Z., Lillicrap D.P., Kaufman R.J., Ochs H.D., Rawlings D.J., and Miao C.H. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol. Ther. 10 1 (2004) 117-126
12. Leong K.W., Mao H.Q., Truong-Le V.L., Roy K., Walsh S.M., and August J.T. DNA-polycation nanospheres as non-viral gene delivery vehicles. J. Control. Release 53 1-3 (1998) 183-193
13. Mansouri S., Lavigne P., Corsi K., Benderdour M., Beaumont E., and Fernandes J.C. Chitosan-DNA nanoparticles as non-viral vectors in gene therapy: strategies to improve transfection efficacy. Eur. J. Pharm. Biopharm. 57 1 (2004) 1-8
14. Borchard G. Chitosans for gene delivery. Adv. Drug Deliv. Rev. 52 2 (2001) 145-150
15. Liu W.G., and Yao K.D. Chitosan and its derivatives-a promising non-viral vector for gene transfection. J. Control. Release 83 1 (2002) 1-11
16. van der Lubben I.M., Verhoef J.C., Borchard G., and Junginger H.E. Chitosan for mucosal vaccination. Adv. Drug Deliv. Rev. 52 2 (2001) 139-144
17. Mao H.Q., Roy K., Troung-Le V.L., Janes K.A., Lin K.Y., Wang Y., August J.T., and Leong K.W. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J. Control. Release 70 3 (2001) 399-421
18. Dodane V., Amin Khan M., and Merwin J.R. Effect of chitosan on epithelial permeability and structure. Int. J. Pharm. 182 1 (1999) 21-32
19. Fang N., Chan V., Mao H.Q., and Leong K.W. Interactions of phospholipid bilayer with chitosan: effect of molecular weight and pH. Biomacromolecules 2 4 (2001) 1161-1168
20. Schipper N.G., Varum K.M., Stenberg P., Ocklind G., Lennernas H., and Artursson P. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. Eur. J. Pharm. Sci. 8 4 (1999) 335-343
21. Thanou M., Verhoef J.C., and Junginger H.E. Chitosan and its derivatives as intestinal absorption enhancers. Adv. Drug Deliv. Rev. 50 Suppl 1 (2001) S91-S101
22. Chew J.L., Wolfowicz C.B., Mao H.Q., Leong K.W., and Chua K.Y. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine 21 21-22 (2003) 2720-2729
23. Roy K., Mao H.Q., Huang S.K., and Leong K.W. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat. Med. 5 4 (1999) 387-391
24. Chen J., Yang W.L., Li G., Qian J., Xue J.L., Fu S.K., and Lu D.R. Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J. Gastroenterol. 10 1 (2004) 112-116
25. Kiang T., Wen J., Lim H.W., and Leong K.W. The effect of the degree of chitosan deacetylation on the efficiency of gene transfection. Biomaterials 25 22 (2004) 5293-5301
26. Toole J.J., Pittman D.D., Orr E.C., Murtha P., Wasley L.C., and Kaufman R.J. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc. Natl. Acad. Sci. U. S. A. 83 16 (1986) 5939-5942
27. Amano K., Sarkar R., Pemberton S., Kemball-Cook G., Kazazian Jr. H.H., and Kaufman R.J. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 91 2 (1998) 538-548
28. Kaufman R.J. Vectors used for expression in mammalian cells. Methods Enzymol. 185 (1990) 487-511
29. Hemker H.C., Giesen P.L., Ramjee M., Wagenvoord R., and Beguin S. The thrombogram: monitoring thrombin generation in platelet-rich plasma. Thromb. Haemost. 83 4 (2000) 589-591
30. Soukharev S., Hammond D., Ananyeva N.M., Anderson J.A., Hauser C.A., Pipe S., and Saenko E.L. Expression of factor VIII in recombinant and transgenic systems. Blood Cells Mol. Diseases 28 2 (2002) 234-248
31. Desai M.P., Labhasetwar V., Amidon G.L., and Levy R.J. Gastrointestinal uptake of biodegradable microparticles: effect of particle size. Pharm. Res. 13 12 (1996) 1838-1845
32. Jani P., Halbert G.W., Langridge J., and Florence A.T. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J. Pharm. Pharmacol. 42 12 (1990) 821-826
33. Hirano S. Chitin biotechnology applications. Biotechnol. Annu. Rev. 2 (1996) 237-258
34. Singla A.K., and Chawla M. Chitosan: some pharmaceutical and biological aspects-an update. J. Pharm. Pharmacol. 53 8 (2001) 1047-1067
35. Truong-Le V.L., Walsh S.M., Schweibert E., Mao H.Q., Guggino W.B., August J.T., and Leong K.W. Gene transfer by DNA-gelatin nanospheres. Arch. Biochem. Biophys. 361 1 (1999) 47-56
36. Lofqvist T., Nilsson I.M., Berntorp E., and Pettersson H. Haemophilia prophylaxis in young patients-a long-term follow-up. J. Intern. Med. 241 5 (1997) 395-400
37. Kaufman R.J. Advances toward gene therapy for hemophilia at the millennium. Hum. Gene Ther. 10 13 (1999) 2091-2107
38. Lynch C.M., Israel D.I., Kaufman R.J., and Miller A.D. Sequences in the coding region of clotting factor VIII act as dominant inhibitors of RNA accumulation and protein production. Hum. Gene Ther. 4 3 (1993) 259-272
39. Miao H.Z., Sirachainan N., Palmer L., Kucab P., Cunningham M.A., Kaufman R.J., and Pipe S.W. Bioengineering of coagulation factor VIII for improved secretion. Blood 103 9 (2004) 3412-3419
40. Alpar H.O., and Bramwell V.W. Current status of DNA vaccines and their route of administration. Crit. Rev. Ther. Drug Carr. Syst. 19 4-5 (2002) 307-383
41. Howard K.A., Li X.W., Somavarapu S., Singh J., Green N., Atuah K.N., Ozsoy Y., Seymour L.W., and Alpar H.O. Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Biochim. Biophys. Acta 1674 2 (2004) 149-157
42. Mathiowitz E., Jacob J.S., Jong Y.S., Carino G.P., Chickering D.E., Chaturvedi P., Santos C.A., Vijayaraghavan K., Montgomery S., Bassett M., and Morrell C. Biologically erodable microspheres as potential oral drug delivery systems. Nature 386 6623 (1997) 410-414
43. Roth D.A., Tawa Jr. N.E., O'Brien J.M., Treco D.A., and Selden R.F. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N. Engl. J. Med. 344 23 (2001) 1735-1742
44. Fakharzadeh S.S., Zhang Y., Sarkar R., and Kazazian Jr. H.H. Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin. Blood 95 9 (2000) 2799-2805
45. Lozier J.N., Yankaskas J.R., Ramsey W.J., Chen L., Berschneider H., and Morgan R.A. Gut epithelial cells as targets for gene therapy of hemophilia. Hum. Gene Ther. 8 12 (1997) 1481-1490
46. James P.D., Raut S., Rivard G.E., Poon M.C., Warner M., McKenna S., Leggo J., and Lillicrap D. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 106 9 (2005) 3043-3048